Q-omics provides the consensus-scored CCDC38 profile across patient tissues and cancer cell-line models. CCDC38 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC38 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC38 RNA expression shows 19,355 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where CCDC38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC38 survival associations across molecular data types. CCDC38 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC38 RNA expression–survival associations across cancer types. High CCDC38 expression shows unfavorable associations in ACC, LUAD and READ, but favorable associations in KIRC, PAAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC38 RNA expression.
This table summarizes CCDC38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC38 shows lower tumor expression in KICH, THCA, BRCA and CHOL and higher tumor expression in HNSC and KIRC. The KICH box plot shows higher CCDC38 RNA expression in normal versus tumor tissue (log2 FC = −0.225, t-test p < 0.001).
This table shows molecular features associated with CCDC38 in patient tissues and cancer cell lines. In patient samples, CCDC38 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
